EA202090916A1 - Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией - Google Patents
Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапиейInfo
- Publication number
- EA202090916A1 EA202090916A1 EA202090916A EA202090916A EA202090916A1 EA 202090916 A1 EA202090916 A1 EA 202090916A1 EA 202090916 A EA202090916 A EA 202090916A EA 202090916 A EA202090916 A EA 202090916A EA 202090916 A1 EA202090916 A1 EA 202090916A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- acetate
- prostate cancer
- androgen
- abirateron
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title abstract 2
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 238000009167 androgen deprivation therapy Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 abstract 1
- 229960000853 abiraterone Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Engineering & Computer Science (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570781P | 2017-10-11 | 2017-10-11 | |
| PCT/US2018/017438 WO2019074536A1 (en) | 2017-10-11 | 2018-02-08 | METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090916A1 true EA202090916A1 (ru) | 2020-12-11 |
Family
ID=61283312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090916A EA202090916A1 (ru) | 2017-10-11 | 2018-02-08 | Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190105332A1 (enExample) |
| EP (1) | EP3694604A1 (enExample) |
| JP (1) | JP2020536903A (enExample) |
| KR (1) | KR20200068689A (enExample) |
| CN (1) | CN111542373A (enExample) |
| AU (1) | AU2018347804A1 (enExample) |
| BR (1) | BR112020007090A2 (enExample) |
| CA (1) | CA3077678A1 (enExample) |
| EA (1) | EA202090916A1 (enExample) |
| IL (1) | IL273826A (enExample) |
| JO (1) | JOP20200072A1 (enExample) |
| MA (1) | MA50341A (enExample) |
| MX (1) | MX2020003830A (enExample) |
| PH (1) | PH12020550151A1 (enExample) |
| UA (1) | UA124865C2 (enExample) |
| WO (1) | WO2019074536A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3014630T3 (en) | 2016-07-29 | 2025-04-23 | Janssen Pharmaceutica Nv | Niraparib for use in a method of treating prostate cancer |
| MX2020003845A (es) | 2017-10-16 | 2020-11-06 | Aragon Pharmaceuticals Inc | Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración. |
| WO2021224469A1 (en) * | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Treatments of prostate cancer with combinations of abiraterone acetate and niraparib |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102898495B (zh) * | 2012-11-12 | 2014-11-26 | 浙江神洲药业有限公司 | 醋酸阿比特龙酯的制备方法 |
-
2018
- 2018-02-08 KR KR1020207012842A patent/KR20200068689A/ko not_active Ceased
- 2018-02-08 WO PCT/US2018/017438 patent/WO2019074536A1/en not_active Ceased
- 2018-02-08 EA EA202090916A patent/EA202090916A1/ru unknown
- 2018-02-08 MA MA050341A patent/MA50341A/fr unknown
- 2018-02-08 CA CA3077678A patent/CA3077678A1/en active Pending
- 2018-02-08 MX MX2020003830A patent/MX2020003830A/es unknown
- 2018-02-08 EP EP18707472.9A patent/EP3694604A1/en not_active Withdrawn
- 2018-02-08 US US15/891,974 patent/US20190105332A1/en not_active Abandoned
- 2018-02-08 AU AU2018347804A patent/AU2018347804A1/en not_active Abandoned
- 2018-02-08 CN CN201880079993.2A patent/CN111542373A/zh active Pending
- 2018-02-08 JO JOP/2020/0072A patent/JOP20200072A1/ar unknown
- 2018-02-08 UA UAA202002743A patent/UA124865C2/uk unknown
- 2018-02-08 JP JP2020520290A patent/JP2020536903A/ja active Pending
- 2018-02-08 BR BR112020007090-4A patent/BR112020007090A2/pt not_active IP Right Cessation
-
2019
- 2019-11-05 US US16/674,323 patent/US20200069704A1/en not_active Abandoned
-
2020
- 2020-03-26 PH PH12020550151A patent/PH12020550151A1/en unknown
- 2020-04-06 IL IL273826A patent/IL273826A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3077678A1 (en) | 2019-04-18 |
| JOP20200072A1 (ar) | 2020-04-29 |
| UA124865C2 (uk) | 2021-12-01 |
| BR112020007090A2 (pt) | 2020-09-24 |
| JP2020536903A (ja) | 2020-12-17 |
| CN111542373A (zh) | 2020-08-14 |
| US20190105332A1 (en) | 2019-04-11 |
| KR20200068689A (ko) | 2020-06-15 |
| MA50341A (fr) | 2020-08-19 |
| AU2018347804A1 (en) | 2020-04-16 |
| MX2020003830A (es) | 2020-11-06 |
| WO2019074536A1 (en) | 2019-04-18 |
| PH12020550151A1 (en) | 2021-02-08 |
| US20200069704A1 (en) | 2020-03-05 |
| IL273826A (en) | 2020-05-31 |
| EP3694604A1 (en) | 2020-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202501583B (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| MA39906A (fr) | Polythérapies pour le traitement du cancer | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| CL2019002871A1 (es) | Terapia combinada para cáncer de próstata. | |
| MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
| MX2018012511A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| GB2568000A (en) | Compositions and methods for treating cancer with arginine depletion and immuno oncology agents | |
| MX2016009515A (es) | Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados. | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| EA202090916A1 (ru) | Способы лечения рака предстательной железы путем введения ацетата абиратерона и преднизона в сочетании с андроген-депривационной терапией | |
| MX2018000135A (es) | Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2). | |
| MY197942A (en) | Adjuvant therapy for use in prostate cancer treatment | |
| BR112022022534A2 (pt) | Tratamentos de câncer de próstata com combinações de acetato de abiraterona e niraparibe | |
| MX2018003308A (es) | Suministro localizado de agente anti-fuctactico para tratamiento del cancer. | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| EA202190294A1 (ru) | Комбинированная терапия для лечения рака | |
| EA201891005A1 (ru) | Комбинированная терапия рака | |
| EA202190291A1 (ru) | Комбинированная терапия для лечения рака | |
| EA201990411A1 (ru) | Способы лечения рака предстательной железы | |
| EA201890956A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей |